The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.

SMJ // Article

Original Article

COVID-19 Patients with Kidney Disease and Completion of Remdesivir Treatment

Authors: Winston Lee, MD, Joshua Fogel, PhD, Alen Shalmiyev, MD, Gaoyuan Huang, MD, Thomas George, MD, Chibuzo Okoye, MD, Yasna Yusuf, MD, Michael Kozlov, BA, Adel El-Hennawy, MD, Elena Frolova, MD

Abstract

Objectives: Remdesivir is a nucleotide analog used to treat coronavirus disease 2019 (COVID-19). We determined whether reduced kidney function is associated with the completion of a full course of remdesivir in hospitalized patients with COVID-19.

Methods: This was a retrospective study of 1103 adults hospitalized with COVID-19. The primary outcome was completion of a full course of remdesivir therapy. Secondary outcomes were in-hospital mortality, length of hospital stay, and liver function tests five times greater than the upper limit of normal. The main predictor variable was glomerular filtration rate (GFR; mL/min), which was categorized as >59, 30 to 59, 15 to 29, and < 15.

Results: The GFR groups of 15 to 29 (odds ratio [OR] 0.59, 95% confidence interval [CI] 0.35–0.996, P = 0.048) and < 15 (OR 0.34, 95% CI 0.16–0.71, P = 0.01) were each significantly associated with decreased odds for the completion of a full course of remdesivir therapy. The GFR groups of 30 to 59 (OR 2.29, 95% CI 1.60–3.27, P < 0.001), 15-29 (OR 4.77, 95% CI 2.77–8.21, P < 0.001), and < 15 (OR 2.41, 95% CI 1.06–5.47, P = 0.04) were each significantly associated with increased odds for mortality. The GFR 15 to 29 group was significantly associated (β = −0.14, standard error = 0.05, P = 0.002) with decreased length of hospital stay. No significant association occurred for GFR and liver function tests.

Conclusions: Individuals with lower GFR had lower odds to receive at least 5 days of remdesivir when compared with those with a GFR >59. We recommend that clinicians be aware that patients with kidney disease may not be able to complete a full course of therapy.
Posted in: Infectious Disease154

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Beigel JH, Tomashek KM, Dodd LE, et al; ACTT-1 study group members. Remdesivir for the treatment of COVID-19—final report. N Engl J Med 2020;383:1813–1826.
 
2. Jorgensen SCJ, Kebriaei R, Dresser LD. Remdesivir: review of pharmacology, pre-clinical data, and emerging clinical experience for COVID-19. Pharmacother J Hum Pharmacol Drug Ther 2020;40:659–671.
 
3. Luke DR, Tomaszewski K, Damle B, et al. Review of the basic and clinical pharmacology of sulfobutylether-beta-cyclodextrin (SBECD). J Pharm Sci 2010;99:3291–3301.
 
4. Ali K, Azher T, Baqi M, et al. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. Can Med Assoc J 2022;194:E242.
 
5. WHO Solidarity Trial Consortium; Pan H, Peto R, et al. Repurposed antiviral drugs for Covid-19—interim WHO solidarity trial results. N Engl J Med 2021;384:497–511.
 
6. Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020;382:2327–2336.
 
7. Zampino R, Mele F, Florio LL, et al. Liver injury in remdesivir-treated COVID-19 patients. Hepatol Int 2020;14:881–883.
 
8. Ohl ME, Miller DR, Lund BC, et al. Association of remdesivir treatment with survival and length of hospital stay among US veterans hospitalized with COVID-19. JAMA Netw Open 2021;4:e2114741.
 
9. Mandadi S, Pulluru H, Annie F. Comparative outcomes of combined corticosteroid and remdesivir therapy with corticosteroid monotherapy in ventilated COVID-19 patients. PloS One 2022;17:e0264301.
 
10. Cheng M, Fowler R, Murthy S, et al. Remdesivir in patients with severe kidney dysfunction: a secondary analysis of the CATCO randomized trial. JAMA Netw Open 2022;5:e2229236.
 
11. Stancampiano F, Jhawar N, Alsafi W, et al. Use of remdesivir for COVID-19 pneumonia in patients with advanced kidney disease: a retrospective multicenter study. Clin Infect Pract 2022;16:100207.
 
12. Aiswarya D, Arumugam V, Dineshkumar T, et al. Use of remdesivir in patients with COVID-19 on hemodialysis: a study of safety and tolerance. Kidney Int Rep 2021;6: 586–593.
 
13. Lim JH, Park SD, Jeon Y, et al. Clinical effectiveness and safety of remdesivir in hemodialysis patients with COVID-19. Kidney Int Rep 2022;7:2522–2525.
 
14. Ng JH, Hirsch JS, Hazzan A, et al. Outcomes among patients hospitalized with COVID-19 and acute kidney injury. Am J Kidney Dis 2021;77:204–215.e1.
 
15. Robbins-Juarez SY, Qian L, King KL, et al. Outcomes for patients with COVID-19 and acute kidney injury: a systematic review and meta-analysis. Kidney Int Rep 2020;5: 1149–1160.